ReviewMedicine2016
Factors affecting patient outcome in primary cutaneous aspergillosis.
Review in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Primary Cutaneous Aspergillosis Due toInfection and drug resistance · 2026Article
- Case Report: Primary Cutaneous Aspergillosis in a Neutropenic Child with Pulmonary Dissemination: A case report.F1000Research · 2026Article
- New Challenges in the Diagnosis and Treatment of Primary Cutaneous Aspergillosis in Extensive Pediatric Burns.Journal of fungi (Basel, Switzerland) · 2025Article
- The Molecular Basis of the Intrinsic and Acquired Resistance to Azole Antifungals inJournal of fungi (Basel, Switzerland) · 2024Article
- Primary Cutaneous Aspergillosis Due toInfection and drug resistance · 2023Article
- Cutaneous aspergillosis masquerading in sporotrichoid morphology in an immunocompetent host.Medical journal, Armed Forces India · 2022Article
- Article
- Primary Cutaneous Aspergillosis in a Patient with CARD9 Deficiency and Aspergillus Susceptibility of Card9 Knockout Mice.Journal of clinical immunology · 2021Article
- Primary cutaneousBMJ case reports · 2020Article
- Primary Cutaneous Aspergillosis in Immunocompetent Adults: Three Cases and a Review of the Literature.Cureus · 2020Article
- Insect Bite-Associated Invasive Fungal Infections.Open forum infectious diseases · 2019Article
- A murine model of cutaneous aspergillosis for evaluation of biomaterials-based local delivery therapies.Journal of biomedical materials research. Part A · 2019Article
- Drug delivery and tissue engineering to promote wound healing in the immunocompromised host: Current challenges and future directions.Advanced drug delivery reviews · 2018Review
- Primary cutaneous aspergillosis caused by Aspergillus.fumigatus in an immunocompetent patient: A case report.Medicine · 2017Article
- Simultaneous primary invasive cutaneous aspergillosis in two preterm twins: case report and review of the literature.BMC infectious diseases · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary cutaneous aspergillosis (PCA) is an uncommon infection of the skin. There is a paucity of organized literature regarding this entity in regard to patient characteristics, associated Aspergillus species, and treatment modalities on outcome (disease recurrence, disease dissemination, and mortality).We reviewed all published reports of PCA from 1967 to 2015. Cases were deemed eligible if they included the following: patient baseline characteristics (age, sex, underlying condition), evidence of proven or probable PCA, primary treatment strategy, and outcome.We identified 130 eligible cases reported from 1967 to 2015. The patients were predominantly male (63.8%) with a mean age of 30.4 ± 22.1 years. Rates of PCA recurrence, dissemination, and mortality were 10.8%, 18.5%, and 31.5%, respectively. In half of the cases, there was an association with a foreign body. Seven different Aspergillus species were reported to cause PCA. Systemic antifungal therapy without surgery was the most common form of therapy (60% of cases). Disease dissemination was more common in patients with underlying systemic conditions and occurred on average 41.4 days after PCA diagnosis (range of 3-120 days). In a multivariate linear regression model of mortality including only patients with immunosuppressive conditions, dissemination and human immunodeficiency virus/acquired immune deficiency syndrome were statistically significantly associated with increased mortality.Nearly one-third of patients with PCA die with the disease. Dissemination and host status are critical in patient outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.